Icovamenib

**Semantic type:** Pharmacologic Substance

**Definition:** An orally bioavailable, irriversible inhibitor of menin, an essential co-factor of oncogenic menin-mixed lineage leukemia (MLL; myeloid/lymphoid leukemia; KMT2A) fusion proteins, with potential antineoplastic activity. Upon oral administration, icovamenib specifically targets and binds to menin, thereby preventing the interaction between the two proteins menin and MLL and the formation of the menin-MLL complex. This reduces the expression of downstream target genes, such as MYC and Bcl2, and results in an inhibition of the proliferation of MLL-rearranged tumor cells. Menin, an essential transcriptional regulator, plays a key role in oncogenic signaling in cancers driven by oncogenic MLL-fusions.

**Synonyms:** - BMF 219 - BMF-219 - BMF219 - ICOVAMENIB - Menin Inhibitor BMF-219 - Menin-MLL Interaction Inhibitor BMF-219